专利检索 ap:("Cliff C. Cheng" OR "Hongbo Zeng" OR "Gerald W. Shipps, Jr." OR "Yongqi Deng" OR "Zhaoyang Meng" OR "Lianyun Zhao" OR "Yang Nan" OR "Binyuan Sun" OR "Duan Liu" OR "Panduranga A. Reddy" OR "M. Arshad Siddiqui") AND inv:"Yongqi Deng" 第 1 页

1.

发明授权
Fused Tricyclic Compounds as novel mTOR inhibitors 有权
标题翻译：融合的三环化合物作为新的mTOR抑制剂

公开(公告)号：US08609675B2

公开(公告)日：2013-12-17

申请号：US13379685

申请日：2010-06-30

申请人： Cliff C. Cheng , Hongbo Zeng , Gerald W. Shipps, Jr. , Yongqi Deng , Zhaoyang Meng , Lianyun Zhao , Yang Nan , Binyuan Sun , Duan Liu , Panduranga A. Reddy , M. Arshad Siddiqui

发明人： Cliff C. Cheng , Hongbo Zeng , Gerald W. Shipps, Jr. , Yongqi Deng , Zhaoyang Meng , Lianyun Zhao , Yang Nan , Binyuan Sun , Duan Liu , Panduranga A. Reddy , M. Arshad Siddiqui

IPC分类号： A01N43/54 , C07D491/00

CPC分类号： C07D487/14

摘要： The present invention provides Fused Tricyclic Compounds of the Formula (I) wherein Q, R1, R2, R3, and R4 are as defined herein, and pharmaceutically acceptable salts of such Fused Tricyclic Compounds. The Fused Tricyclic Compounds are useful in the treatment of cancer and other proliferative disorders.

摘要翻译： 本发明提供了其中Q，R 1，R 2，R 3和R 4如本文所定义的式（I）的稠合三环化合物和这种稠合三环化合物的药学上可接受的盐。融合的三环化合物可用于治疗癌症和其他增殖性疾病。

2.

发明申请
FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS 有权
标题翻译：熔融三氯化合物作为新型抑制剂

公开(公告)号：US20120178744A1

公开(公告)日：2012-07-12

申请号：US13379685

申请日：2010-06-30

申请人： Cliff C. Cheng , Hongbo Zeng , Gerald W. Shipps, JR. , Yongqi Deng , Zhaoyang Meng , Lianyun Zhao , Yang Nan , Binyuan Sun , Duan Liu , Panduranga A. Reddy , M. Arshad Siddiqui

发明人： Cliff C. Cheng , Hongbo Zeng , Gerald W. Shipps, JR. , Yongqi Deng , Zhaoyang Meng , Lianyun Zhao , Yang Nan , Binyuan Sun , Duan Liu , Panduranga A. Reddy , M. Arshad Siddiqui

IPC分类号： A61K31/541 , A61K31/519 , A61P35/00 , C07D487/14

CPC分类号： C07D487/14

摘要： The present invention provides Fused Tricyclic Compounds of the Formula (I) wherein Q, R1, R2, R3, and R4 are as defined herein, and pharmaceutically acceptable salts of such Fused Tricyclic Compounds. The Fused Tricyclic Compounds are useful in the treatment of cancer and other proliferative disorders.

摘要翻译： 本发明提供了其中Q，R 1，R 2，R 3和R 4如本文所定义的式（I）的稠合三环化合物和这种稠合的三环化合物的药学上可接受的盐。融合的三环化合物可用于治疗癌症和其他增殖性疾病。

3.

发明授权
Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors 有权
标题翻译：吡唑并[1,5-a]嘧啶衍生物，为mTOR抑制剂

公开(公告)号：US08591943B2

公开(公告)日：2013-11-26

申请号：US13263193

申请日：2010-04-08

申请人： Yongqi Deng , Binyuan Sun , Hongbo Zeng , Matthew Richards , Gerald W. Shipps, Jr. , Cliff C. Cheng , Yinyan Zhao , Andrew McRiner , Zhaoyang Meng , Yang Nan , Mehul F. Patel , Iwona E. Wrona , Panduranga Adulla Reddy , Brian M. Eklov , Shuyi Tang , Duan Liu , Amit K. Mandal , Lianyun Zhao , M. Arshad Siddiqui

发明人： Yongqi Deng , Binyuan Sun , Hongbo Zeng , Matthew Richards , Gerald W. Shipps, Jr. , Cliff C. Cheng , Yinyan Zhao , Andrew McRiner , Zhaoyang Meng , Yang Nan , Mehul F. Patel , Iwona E. Wrona , Panduranga Adulla Reddy , Brian M. Eklov , Shuyi Tang , Duan Liu , Amit K. Mandal , Lianyun Zhao , M. Arshad Siddiqui

IPC分类号： A61K9/127 , A61K39/395 , A61K31/554 , A61K31/541 , A61K31/5377 , A61K38/50 , A61K31/553 , A61K33/24 , A61K31/704 , A61K31/551 , A61K31/538 , A61K31/519

CPC分类号： C07D487/04 , C07D519/00

摘要： The present invention provides methods for inhibiting mTOR using pyrazolo[1,5-a]pyrimidine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with mTOR using such compounds.

摘要翻译： 本发明提供使用吡唑并[1,5-a]嘧啶化合物抑制mTOR的方法以及使用这些化合物治疗，预防，抑制或改善与mTOR相关的一种或多种疾病的方法。

4.

发明申请
PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS 有权
标题翻译：吡咯并[1,5-a]吡啶衍生物作为mTOR抑制剂

公开(公告)号：US20120114739A1

公开(公告)日：2012-05-10

申请号：US13263193

申请日：2010-04-08

申请人： Yongqi Deng , Binyuan Sun , Hongbo Zeng , Matthew Richards , Gerald W. Shipps, JR. , Cliff C. Cheng , Yinyan Zhao , Andrew McRiner , Zhaoyang Meng , Yang Nan , Mehul F. Patel , Iwona E. Wrona , Panduranga Adulla Reddy , Brian M. Eklov , Shuyi Tang , Duan Liu , Amit K. Mandal , Lianyun Zhao , M. Asshad Siddiqui

发明人： Yongqi Deng , Binyuan Sun , Hongbo Zeng , Matthew Richards , Gerald W. Shipps, JR. , Cliff C. Cheng , Yinyan Zhao , Andrew McRiner , Zhaoyang Meng , Yang Nan , Mehul F. Patel , Iwona E. Wrona , Panduranga Adulla Reddy , Brian M. Eklov , Shuyi Tang , Duan Liu , Amit K. Mandal , Lianyun Zhao , M. Asshad Siddiqui

IPC分类号： A61K9/127 , A61K31/519 , A61K31/5377 , C07D491/048 , C07D495/04 , A61K31/538 , A61K31/551 , A61K31/553 , A61K31/541 , A61K31/554 , C07D498/04 , C12N9/99 , A61K31/704 , A61K39/395 , A61K33/36 , A61K38/50 , A61K33/24 , A61P29/00 , A61P37/08 , A61P11/00 , A61P37/06 , A61P35/00 , A61P35/02 , C07D487/04

CPC分类号： C07D487/04 , C07D519/00

摘要： The present invention provides methods for inhibiting mTOR using pyrazolo[1,5-a]pyrimidine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with mTOR using such compounds.

摘要翻译： 本发明提供使用吡唑并[1,5-a]嘧啶化合物抑制mTOR的方法以及使用这些化合物治疗，预防，抑制或改善与mTOR相关的一种或多种疾病的方法。

5.

发明授权
High affinity thiophene-based and furan-based kinase ligands 失效
标题翻译：高亲和力噻吩类和呋喃类激酶配体

公开(公告)号：US07446195B2

公开(公告)日：2008-11-04

申请号：US11505263

申请日：2006-08-16

申请人： Yongqi Deng , Lianyun Zhao , Gerald W. Shipps, Jr. , Patrick J. Curran , M. Arshad Siddiqui , Rumin Zhang , Charles W. McNemar , Todd W. Mayhood , William T. Windsor , Emma M. Lees , David A. Parry

发明人： Yongqi Deng , Lianyun Zhao , Gerald W. Shipps, Jr. , Patrick J. Curran , M. Arshad Siddiqui , Rumin Zhang , Charles W. McNemar , Todd W. Mayhood , William T. Windsor , Emma M. Lees , David A. Parry

IPC分类号： C07D413/12 , C07D403/12 , C07D409/12 , C07D405/12

CPC分类号： C07D405/12 , C07D333/40 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14

摘要： Inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2, and methods for treating disease or disease symptoms.

摘要翻译： 描述了细胞周期蛋白依赖性激酶2的抑制剂，包括抑制剂的组合物，以及使用抑制剂和抑制剂组合物的方法。包括它们的抑制剂和组合物可用于治疗疾病或疾病症状。本发明还提供了制备CDK-2抑制剂化合物的方法，抑制CDK-2的方法以及治疗疾病或疾病症状的方法。

6.

发明授权
High affinity quinoline-based kinase ligands 有权
标题翻译：高亲和力喹啉类激酶配体

公开(公告)号：US07511063B2

公开(公告)日：2009-03-31

申请号：US11504869

申请日：2006-08-16

申请人： Yongqi Deng , Patrick J. Curran , Gerald W. Shipps, Jr. , Lianyun Zhao , M. Arshad Siddiqui , Janeta Popovici-Muller , Jose S. Duca , Alan W. Hruza , Thierry O. Fischmann , Vincent S. Madison , Rumin Zhang , Charles W. McNemar , Todd W. Mayhood , William T. Windsor , Emma M. Lees , David A. Parry

发明人： Yongqi Deng , Patrick J. Curran , Gerald W. Shipps, Jr. , Lianyun Zhao , M. Arshad Siddiqui , Janeta Popovici-Muller , Jose S. Duca , Alan W. Hruza , Thierry O. Fischmann , Vincent S. Madison , Rumin Zhang , Charles W. McNemar , Todd W. Mayhood , William T. Windsor , Emma M. Lees , David A. Parry

IPC分类号： A61K31/47 , C07D215/14

CPC分类号： C07D409/04 , C07D215/48 , C07D215/50 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/04 , C07D409/12 , C07D409/14 , C07D413/10 , C07D413/12 , C07D417/04 , C07D417/06 , C07D417/10

摘要： Quinoline-based inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2, and methods for treating disease or disease symptoms.

摘要翻译： 描述了基于喹啉的细胞周期蛋白依赖性激酶2抑制剂，包括抑制剂的组合物，以及使用抑制剂和抑制剂组合物的方法。包括它们的抑制剂和组合物可用于治疗疾病或疾病症状。本发明还提供了制备CDK-2抑制剂化合物的方法，抑制CDK-2的方法以及治疗疾病或疾病症状的方法。

7.

发明授权
Compounds that are ERK inhibitors 有权
标题翻译： ERK抑制剂的化合物

公开(公告)号：US08546404B2

公开(公告)日：2013-10-01

申请号：US11810282

申请日：2007-06-05

申请人： Alan B. Cooper , Yongqi Deng , Gerald W. Shipps, Jr. , Neng-Yang Shih , Hugh Y. Zhu , Robert Sun , Joseph M. Kelly , Ronald J. Doll , Yang Nan , Tong Wang , Jagdish A. Desai , James J-S Wang , Youhao Dong , Vincent S. Madison , Li Xiao , Alan W. Hruza , M. Arshad Siddiqui , Ahmed A. Samatar , Sunil Paliwal , Hon-Chung Tsui , Azim Alan Celebi , Yiji Wu , Sobhana Babu Boga , Abdul-Basit Alhassan , Xiaolei Gao , Liang Zhu , Mehul Patel

发明人： Alan B. Cooper , Yongqi Deng , Gerald W. Shipps, Jr. , Neng-Yang Shih , Hugh Y. Zhu , Robert Sun , Joseph M. Kelly , Ronald J. Doll , Yang Nan , Tong Wang , Jagdish A. Desai , James J-S Wang , Youhao Dong , Vincent S. Madison , Li Xiao , Alan W. Hruza , M. Arshad Siddiqui , Ahmed A. Samatar , Sunil Paliwal , Hon-Chung Tsui , Azim Alan Celebi , Yiji Wu , Sobhana Babu Boga , Abdul-Basit Alhassan , Xiaolei Gao , Liang Zhu , Mehul Patel

IPC分类号： A01N43/54 , C07D239/42 , C07D401/04

CPC分类号： C07D231/56 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/14

摘要： Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

摘要翻译： 公开了式1.0的ERK抑制剂及其药学上可接受的盐，酯和溶剂化物。 Q是可以具有桥或稠合环的哌啶或哌嗪环。哌啶环可以在环中具有双键。所有其他取代基如本文所定义。还公开了使用式1.0化合物治疗癌症的方法。

8.

发明授权
Compounds that are ERK inhibitors 失效
标题翻译： ERK抑制剂的化合物

公开(公告)号：US07807672B2

公开(公告)日：2010-10-05

申请号：US11705709

申请日：2007-02-13

申请人： Yongqi Deng , Gerald W. Shipps, Jr. , Alan Cooper , Yang Nan , Tong Wang , M. Arshad Siddiqui , Hugh Zhu , Robert Sun , Joseph M. Kelly , Ronald Doll , Jagdish Desai , James J-S Wang , Youhao Dong , Vincent Madison , Li Xiao , Alan Hruza , Neng-Yang Shih

发明人： Yongqi Deng , Gerald W. Shipps, Jr. , Alan Cooper , Yang Nan , Tong Wang , M. Arshad Siddiqui , Hugh Zhu , Robert Sun , Joseph M. Kelly , Ronald Doll , Jagdish Desai , James J-S Wang , Youhao Dong , Vincent Madison , Li Xiao , Alan Hruza , Neng-Yang Shih

IPC分类号： A61K31/506 , A61K31/5377 , A61K31/4025 , A61K31/496 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D413/12 , C07D417/06 , C07D417/12

CPC分类号： C07D207/16 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D487/08

摘要： Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substituents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

摘要翻译： 公开了式1.0的ERK抑制剂及其药学上可接受的盐和溶剂化物。 Q是可以具有桥或稠合环的哌啶或哌嗪环。哌啶环可以在环中具有双键。所有其它取代基如本文所定义。还公开了使用式1.0化合物治疗癌症的方法。